Showing results (291-300 of 369) with videos related to
Sort By:
Pageof 37
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 20, 2021
Differences in Prostate Cancer Genomes by Self-reported Race: Contributions of Genetic Ancestry, Modifiable Cancer Risk Factors, and Clinical FactorsKonrad H Stopsack, Subhiksha Nandakumar, Kanika Arora, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 18, 2010
Significant and sustained antitumor activity in post-docetaxel, castration-resistant prostate cancer with the CYP17 inhibitor abiraterone acetateAlison H M Reid, Gerhardt Attard, Daniel C Danila, et al.European Urology|October 29, 2015
Prior Endocrine Therapy Impact on Abiraterone Acetate Clinical Efficacy in Metastatic Castration-resistant Prostate Cancer: Post-hoc Analysis of Randomised Phase 3 StudiesJoaquim Bellmunt, Thian Kheoh, Margaret K Yu, et al.The Journal of Clinical Investigation|June 9, 2007
Improved prediction of prostate cancer recurrence through systems pathologyCarlos Cordon-Cardo, Angeliki Kotsianti, David A Verbel, et al.European Urology|December 12, 2018
Cabozantinib Versus Mitoxantrone-prednisone in Symptomatic Metastatic Castration-resistant Prostate Cancer: A Randomized Phase 3 Trial with a Primary Pain EndpointEthan M Basch, Mark Scholz, Johann S de Bono, et al.Cancer Cell|November 21, 2017
Aberrant Activation of a Gastrointestinal Transcriptional Circuit in Prostate Cancer Mediates Castration ResistanceShipra Shukla, Joanna Cyrta, Devan A Murphy, et al.Journal of Translational Medicine|July 4, 2012
Considerations in the development of circulating tumor cell technology for clinical useDavid R Parkinson, Nicholas Dracopoli, Brenda Gumbs Petty, et al.European Urology|March 18, 2014
Effects of cabozantinib on pain and narcotic use in patients with castration-resistant prostate cancer: results from a phase 2 nonrandomized expansion cohortEthan Basch, Karen A Autio, Matthew R Smith, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 21, 2018
A Phase II Trial of the Aurora Kinase A Inhibitor Alisertib for Patients with Castration-resistant and Neuroendocrine Prostate Cancer: Efficacy and BiomarkersHimisha Beltran, Clara Oromendia, Daniel C Danila, et al.European Urology|August 20, 2020
Final Analysis of the Ipilimumab Versus Placebo Following Radiotherapy Phase III Trial in Postdocetaxel Metastatic Castration-resistant Prostate Cancer Identifies an Excess of Long-term SurvivorsKarim Fizazi, Charles G Drake, Tomasz M Beer, et al.Pageof 37